Inogen changes up board of directors 

GOLETA, Calif. – Inogen has appointed Glenn Boehnlein, Kevin King and Mary Katherine Ladone to its board of directors. In conjunction with these appointments, Heath Lukatch, a director since 2006; Benjamin Anderson-Ray, a director since 2013; and Loren McFarland, a director since 2013, have all retired from the board. “Maintaining a board with diverse, fresh perspectives, skills, and experience to drive shareholder value is of utmost priority for Inogen and we are thrilled to welcome Glenn, Kevin and Mary Kay to the Inogen board,” said Elizabeth Mora, chairwoman of the board. “Each of them brings unique experiences and an extensive track record of helping guide and grow successful med-tech companies, which we believe positions them to support our overarching goal of transforming Inogen into a prominent leader in respiratory care.” Inogen has also reconstituted the committees of the board. The committee chairs will be Glenn Boehnlein for the Audit Committee, Kevin King for the Compensation Committee, Heather Rider for the Nominating & Governance Committee and Elizabeth Mora for the Compliance Committee. The company is maintaining the total number of members on its board of directors at seven. Boehnlein currently serves as vice president, CFO, at Stryker Corp. King served as CEO and president at iRhythm Technologies until 2021. He recently retired from the company’s board of directors. Ladone served as corporate officer and senior vice president of corporate development, strategy and investor relations at Hill-Rom Holdings, which is now a subsidiary of Baxter International.